3 not yet recruiting, 2 completed, 2 recruiting, 1 withdrawn. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow MZL: new trials by email Literature Review of MZL trials Research Report on MZL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma - DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 40 | 2026-08-30 | 2026-08-06 |
| Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma Lisaftoclax - Indolent Lymphoma, WM | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 75 | 2026-07-10 | 2026-07-29 |
| CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma R2/BR/OR2 - MZL | Not yet recruiting | Henan Cancer Hospital | 131 | 2026-04-01 | 2026-03-25 | |
| Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 33 | 2026-02-11 | 2026-03-13 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) ICP-022 - MZL | Phase 2 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 111 | 2019-04-01 | 2024-04-18 |
| Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Zanubrutinib - Marginal Zone Lymphoma, MZL | Phase 2 | Completed | BeiGene | 68 | 2019-02-19 | 2024-10-26 |
Lymphoma, B-Cell, Marginal Zone (3) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (4) · Lymphatic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoma, B-Cell (3) · Lymphoproliferative Disorders (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1)
Lisaftoclax (1) · Rituximab (1) · pirtobrutinib (1) · venetoclax (1) · zanubrutinib (1)
Henan Cancer Hospital (2) · BeiGene (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Changzhou No.2 People's Hospital (1) · Gottfried von Keudell, MD PhD (1) · Hutchmed (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
China (5) · United States (3) · Australia (2) · France (2) · Italy (2) · Czechia (1) · Israel (1) · New Zealand (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Gottfried von Keudell, MD, PhD (1) · Jun Zhu, PhD (1) · Vijay Jayaprakash, MBBS, PHD (1)
PMID 37682792, PMID 38502198, PMID 40550489
2018 (1)